Expertise in
7
conditions

Dr. Margaret V. Ragni

Internal Medicine
Hillman Center Pharmacy
5115 Centre Ave, 
Pittsburgh, PA 
Expertise in
7
conditions
Hillman Center Pharmacy
5115 Centre Ave, 
Pittsburgh, PA 

Overview

Margaret Ragni is a primary care provider, practicing in Internal Medicine in Pittsburgh, Pennsylvania.

Dr. Ragni is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Hemophilia A, Blood Clots, Von Willebrand Disease (VWD), Hemophilia B, and Liver Transplant.

She is actively involved in clinical research, co-authoring 162 peer reviewed articles and participating in 14 clinical trials.

Specialties

Internal Medicine

Licenses

Specialist in PA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UPMC
  • EPO
  • PPO

Locations

Hillman Center Pharmacy
5115 Centre Ave, Pittsburgh, PA 15232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)
ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)
Enrollment Status: Completed
Publish Date: July 13, 2026
Prospective, Randomized Trial Comparing Recombinant Von Willebrand Factor (rVWF) Plus Tranexamic Acid vs. rVWF Alone to Reduce Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Prospective, Randomized Trial Comparing Recombinant Von Willebrand Factor (rVWF) Plus Tranexamic Acid vs. rVWF Alone to Reduce Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Drug
Study Drugs: Recombinant Von Willebrand factor, Tranexamic Acid
Study Phase: Phase 3
A Phase 1, Open-Label Study to Assess the Pharmacokinetics, and Safety and Tolerability of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
A Phase 1, Open-Label Study to Assess the Pharmacokinetics, and Safety and Tolerability of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drug: Efanesoctocog alfa (BIVV001)
Study Phase: Phase 1
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
Enrollment Status: Completed
Publish Date: February 12, 2025
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study
Enrollment Status: Terminated
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: Von Willebrand Factor, Tranexamic Acid
Study Phase: Phase 3
An Observational Cohort Study of Long-Term Outcomes of Orthotopic Liver Transplantation in People With Hemophilia
An Observational Cohort Study of Long-Term Outcomes of Orthotopic Liver Transplantation in People With Hemophilia
Enrollment Status: Completed
Publish Date: May 10, 2023
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A
Enrollment Status: Terminated
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drugs: Eloctate ITI, Emicizumab
Study Phase: Phase 3
Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia A
Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia A
Enrollment Status: Terminated
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drugs: Eloctate ITI, Emicizumab
Study Phase: Phase 3
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
Enrollment Status: Completed
Publish Date: December 09, 2021
Intervention Type: Biological
A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
Enrollment Status: Completed
Publish Date: May 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

162 Total Publications

Infrastructure and workforce development processes inspired by Lived Experience Experts and grounded in health equity for the Bleeding Disorders Research Collaborative.
Infrastructure and workforce development processes inspired by Lived Experience Experts and grounded in health equity for the Bleeding Disorders Research Collaborative.
Journal: Expert review of hematology
Published: August 07, 2026
Similar Doctors
Expertise in
5
conditions
Dr. John M. Kirkwood
Internal Medicine
Expertise in
5
conditions
Dr. John M. Kirkwood
Internal Medicine
Before you request

Upmc Division Of Surgical Oncology

5115 Centre Ave, Ste 2, 
Pittsburgh, PA 
 (0.1 miles away)
Languages Spoken:
English, German, Italian
See accepted insurances
Accepting New Patients
Offers Telehealth

John M. Kirkwood, MD, is a professor of medicine, dermatology, and clinical and translational science at the University of Pittsburgh School of Medicine and the Clinical and Translational Science Institute at the University of Pittsburgh. Dr. Kirkwood directs the Melanoma Center at UPMC Hillman Cancer Center and specializes in melanoma research and the prevention and early detection of melanoma, as well as the treatment of advanced disease and adjuvant therapy of resectable disease. Dr. Kirkwood is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Melanoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Uveal Melanoma. Dr. Kirkwood is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Kirkwood is currently accepting new patients.

Expertise in
8
conditions
Dr. John S. Gill
Internal Medicine
Expertise in
8
conditions
Dr. John S. Gill
Internal Medicine

Premier Medical Associates PC

2570 Haymaker Rd, 
Monroeville, PA 
 (10.4 miles away)
412-858-7618
Experience:
17+ years
Languages Spoken:
English, Spanish
See accepted insurances

John Gill is a primary care provider, practicing in Internal Medicine in Monroeville, Pennsylvania. He has been practicing medicine for over 17 years. Dr. Gill is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Chronic Kidney Disease, Gangrene, Hepatitis C, Kidney Transplant, and Nephrectomy. Dr. Gill is board certified in American Board Of Internal Medicine - Internal Medicine.

Expertise in
10
conditions
Dr. David L. Paterson
Internal Medicine
Expertise in
10
conditions
Dr. David L. Paterson
Internal Medicine

UPMC Montefiore

3459 5th Ave, 
Pittsburgh, PA 
 (1.4 miles away)
412-643-6401
Languages Spoken:
English
See accepted insurances

David Paterson is a primary care provider, practicing in Internal Medicine in Pittsburgh, Pennsylvania. Dr. Paterson is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Sepsis, Pseudomonas Stutzeri Infections, Urinary Tract Infection (UTI), and Methicillin-Resistant Staphylococcus Aureus (MRSA).

Frequently Asked Questions about Dr. Margaret V. Ragni

How do I make an appointment with Dr. Margaret V. Ragni?

You can book an appointment with Dr. Margaret V. Ragni by calling their office at 412-692-4724. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Margaret V. Ragni a top-rated expert for Hemophilia A?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Margaret V. Ragni is classified as an Elite expert for Hemophilia A, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Margaret V. Ragni specialize in?

While Dr. Margaret V. Ragni is a Internal Medicine, they have specific expertise in Hemophilia A, Blood Clots, and Von Willebrand Disease (VWD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Margaret V. Ragni participate in research or clinical trials?

Yes. Dr. Margaret V. Ragni has published 162 articles and abstracts on conditions like Hemophilia A. You can view a list of Dr. Margaret V. Ragni's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Margaret V. Ragni accept my insurance?

Dr. Margaret V. Ragni accepts most major insurance plans, including Humana and UPMC. We recommend calling the office directly at 412-692-4724 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ragni's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile